Given that the principal mechanisms of hypercalcemia in cancer patients are related to the secretion of PTHrP by tumor cells and very rarely to the secretion of calcitriol, it is mandatory to identify promptly the hypercalcemia-related symptoms and the underling paraneoplastic secretion. This evidence concerns the gene PTHLH and hypercalcemia disease.